Kannapolis R&D Tax Credit Benefits for Businesses

R&D Tax Credits for Kannapolis, North Carolina Businesses

Kannapolis, North Carolina, thrives in industries such as healthcare, education, manufacturing, retail, and biotechnology. Top companies in the city include Atrium Health, a leading healthcare provider; Rowan-Cabarrus Community College, a major educational institution; the North Carolina Research Campus, a significant biotechnology employer; the North Carolina Research Campus, a key player in the manufacturing sector; and the North Carolina Research Campus, a prominent biotechnology company. The R&D Tax Credit can provide tax savings for these industries by incentivizing innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 6255 Towncenter Drive, Clemmons, North Carolina is less than 65 miles away from Kannapolis and provides R&D tax credit consulting and advisory services to Kannapolis and the surrounding areas such as: Greensboro, Winston-Salem, High Point, Concord and Gastonia.

If you have any questions or need further assistance, please call or email our local North Carolina Partner on (984) 480-4601.
Feel free to book a quick teleconference with one of our North Carolina R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Kannapolis, North Carolina Patent of the Year – 2024/2025

Coddle Creek Capital LLC has been awarded the 2024/2025 Patent of the Year for advancing healthcare innovation. Their invention, detailed in U.S. Patent Application No. 20240131043, titled ‘Spiral steroids and precursors thereof for clinical diagnosis and treatment of necrotizing enterocolitis and pre-eclampsia’, introduces a novel class of compounds designed to diagnose and treat two life-threatening conditions.

This breakthrough focuses on spiral steroids, a new molecular structure with targeted therapeutic properties. The compounds offer promising new strategies for treating necrotizing enterocolitis in infants and pre-eclampsia in pregnant women. Both conditions currently lack effective early treatment options and are associated with high risk and limited intervention windows.

The invention allows for early detection and intervention by identifying unique biomarkers tied to these diseases. Once detected, the spiral steroid compounds can be used to halt or reverse disease progression with fewer side effects than traditional steroid therapies.

This innovation could dramatically improve outcomes in neonatal and maternal care. By combining diagnosis and treatment in one streamlined approach, the technology reduces delays and increases survival rates. It also opens new paths for research into inflammatory and vascular conditions that share similar biological mechanisms.

Coddle Creek Capital LLC’s development represents a bold step toward precision medicine and reflects their commitment to solving complex healthcare challenges with targeted, science-driven solutions.